Current research indicates that when dosage and administration are appropriately managed, recreational psychedelics such as LSD (lysergic acid diethylamide), MDMA (3,4-Methylenedioxymethamphetamine), sometimes referred to as “Molly,” and psilocybin, sometimes referred to as “Shrooms,” are producing positive results. Is the use of psychedelics a viable strategy in the fight against depression and PTSD given the growing global nature of the issue and the lack of new antidepressant classes in the last thirty years?, buy psychedelics for depression colorado here.

Why does mental health matter? A growing problem and opportunity

The foundation of a strong and prosperous economy is a healthy population. However, over 280 million people worldwide suffer from depression, and 284 million are thought to have experienced post-traumatic stress disorder (PTSD), according to the World Health Organization (WHO). It is commonly recognized that mental illness has an adverse effect on an individual’s capacity to work and can severely restrict their involvement in the labor force.Since PTSD remission rates range from 20 to 30 percent, a growing number of people are seeking treatment for depression, which is actually the primary cause of disability globally.

Consequently, one could argue that it is imperative to address the growing mental health crisis. Adolescents and young adults now experience much higher rates of mental illness than they did in the past.

The status quo: Treatment resistance with current anti-depressants

More than thirty years have passed without the development of a new class of antidepressant drugs. For many years, Prozac and other selective serotonin reuptake inhibitors (SSRIs) have been the mainstay of the antidepressant drug market. A crucial hormone called serotonin stabilizes our mood, feelings, and happiness by activating serotonin receptors in specific brain regions (Figure 1).

In order to raise the amount of serotonin at the synapses, the SSRI medications block the reuptake of serotonin (5-HT) at the neuronal synapses (Figure 1). However, after receiving these prescriptions for many years, a large number of patients have developed treatment resistance to these drugs, which is creating a significant demand for alternative forms of treatment. Is using psychedelics one of those methods?

Promising results in early clinical trials

Since 1990, there has been a surge in interest in psychedelic drugs among researchers because of the advancements in neuroimaging technology, which have made it possible to connect these drugs to real outcomes in an experimental setting. These medications belong to a class of hallucinogenic substances that bind to certain neurotransmitter receptors to produce their neurological effects (receptors sensing chemical signals between neurons). Following consumption, they alter perception, mood, and cognitive function and have the potential to induce a “psychedelic trip,” which is a delusional state of mind. These medications are made of synthetic or naturally occurring organic chemical compounds.

Psychedelic drugs are seeing a resurgence in popularity due to the growing awareness of mental health issues and the current state of insufficient treatments:

• Psilocybin (shrooms) for the treatment of drug-resistant depression in phase 2 trials
• Lysergic acid diethylamide (LSD) for the treatment of major depressive disorder in phase 2 trials
• 3,4-Methylenedioxymethamphetamine (MDMA) a key ingredient in the drug commonly known as ecstasy or molly, for the treatment of PTSD patients in phase 3 trials.

Mushrooming potential for psilocybin

Its chemical structure is very similar to serotonin, which enables it to act as a serotonin receptor agonist. After being consumed, psilocybin is converted into the active drug form of psilocin (Figure 2). Just the locations of the hydroxyl and methyl groups distinguish the structures from one another (Figure 3). Psilocybin causes profound delusions, including both visual and auditory hallucinations, over a few hours after consumption, shop here.

Large, quick, and long-lasting antidepressant effects were observed in patients with major depressive disorder receiving psilocybin-assisted therapy, according to results from a randomized clinical trial. For major depressive disorder, psilocybin is currently being studied in phase 2 clinical trials. Furthermore, there have been encouraging results in treating alcohol and nicotine addiction in a number of pilot studies involving psilocybin-assisted psychotherapy.

Early outcomes showed of LSD

MDMA moves beyond raves

Progress, but more work required

Even with recent advancements, there are still certain obstacles to overcome before psychedelics can be used to treat mental health conditions. First off, a lot of these substances are illegal schedule 1 substances outside of Oregon. Second, there is a great chance that both patients and healthcare professionals will abuse, neglect, or misuse highly controlled substances. And lastly, there are risks related to your physical health. Occasionally, a small percentage of patients may have a moderate rise in heart rate and blood pressure or have a “bad trip,” which is defined as an acute state of anxiety and confusion.

Long-term or frequent use of psychedelic drugs may result in tolerance, even though they do not have the same negative effects on withdrawal or dependency as opioids or cannabis substances do. It is suggested that psychedelic substances .